In March, 2004, Solae, a joint venture of Dupont and Bunge, submitted a petition to the FDA for a Soy Protein and Cancer Health Claim. In their petition, they note that since the FDA authorized the Soy Protein and Coronary Heart Disease Health Claim, per capita consumption of soy protein increased from 0.78 g/day in 1998 to 2.23 g/day in 2002. Solae predicts that consumption of soy protein will double with a cancer health claim. Solae is one of the world’s largest producers of soy protein isolate (SPI) and other processed soy products.
On April 14, the Weston A. Price Foundation submitted a rebuttal to the Solae petition, urging the FDA to deny the company’s request. The report was prepared by Kaayla T. Daniel, PhD, who noted that “Solae was highly selective in its choice of evidence and biased in its interpretations. It omitted many studies that show soy to be ineffective in preventing cancer, emphasized favorable outcome in studies when results were mixed and excused results of a few unfavorable studies that they included to give the illusion of balance. Most seriously, Solae omitted many well-designed studies that have suggested that soy protein can contribute to, cause and accelerate the growth of cancer.” Our 50-page response lists numerous studies implicating soy protein as a contributor to cancers of the breast, prostate and gastrointestinal tract.
The report is posted on our website at www.westonaprice.org.
The FDA must respond within 270 days, or by November 26, 2004.